An observational study in Hepatocellular Carcinoma, sponsored by Seoul National University Hospital. Completed at 3 sites in South Korea. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-06-25.
Sponsored by Seoul National University Hospital · Observational
This prospective multicenter study aimed to compare the diagnostic performance of non-contrast abbreviated MRI in detecting recurrent HCC after curative treatment to that of contrast-enhanced liver CT.
This study was designed as a prospective single-arm intra-individual comparison multicenter study
3,249 studies on the registry are indexed under Carcinoma, Hepatocellular; 974 are open to participants now.
This study's enrollment of 210 is close to the median of 200 across 769 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Seoul National University Hospital is the lead sponsor of 1,897 studies on the registry; 273 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients who underwent curative treatment for HCC including surgical resection or local ablation and have a more than a two-year disease-free period, needing continuous surveillance for the development of HCC will be candidates for this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Liver MRI without contrast injection. The following sequences will be obtained from all of the participants. * Axial heavily and regular T2 WI * precontrast fat-suppressed T1 WI * Diffusion-weighted image using b-value of 0, 50 or 400, and 800 or 1000
Liver CT with iodine contrast injection This test will be served as a standard diagnostic test. The following phases will be obtained * precontast, arterial phase, portal venous phase and delayed phase
Accuracy per patient
Accuracy for detection of recurrent HCC per patient
Time frame: Within 6 months from the study completion
Specificity per patient
Specificity for detection of recurrent HCC per patient
Time frame: Within 6 months from the study completion
Sensitivity per patient
Sensitivity for detection of recurrent HCC per patient
Time frame: Within 6 months from the study completion
Plan to share: Undecided — Individual participant data (IPD) of this study will be available for reasonable requests after approval of IRB
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Jun 2024, 29 months.
Of 273 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 112. This study's 29 months is below that.
Counting every sponsor, half of 313 studies reached it within 50 months; a quarter within 32 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →